SKU: C-1168-5mg
GSK-2636771 Chemical Formula: C22H22F3N3O3
  • Catalog#: C-1168
  • Targets: PI3K
  • Synonym: GSK2636771; GSK-2636771; GSK 2636771
  • Chemical Name/IUPAC:2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid
    Technical Data
  • Product Name: GSK-2636771
  • Chemical Formula: C22H22F3N3O3
  • Molecular Weight: 433.42
  • CAS#: 1372540-25-4
  • Appearance: Solid powder
  • Purity: > 99% by HPLC
  • Solubility: Soluble in DMSO
  • Storage: Room temperature for months, or -20ºC for 3 years
    GSK-2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK-2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.